Biological activity of pyrazole and imidazole-dehydroepiandrosterone derivatives on the activity of 17β-hydroxysteroid dehydrogenase

References

• Chang K-H, Li R, Papari-Zareei M, et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Nat Acad Sci 2011;108:13728–33
   PubMed Web of Science ®Google Scholar
• Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009;6:76–85
   PubMedGoogle Scholar
• Zong Y, Goldstein AS. Adaptation or selection—mechanisms of castration-resistant prostate cancer. Nat Rev Urol 2013;10:90–8
   PubMed Web of Science ®Google Scholar
• Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 2013;32:5501–11
   PubMed Web of Science ®Google Scholar
• Kikuchi A, Furutani T, Azami H, et al. In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). Invest New Drugs 2014;32:860–70
   PubMed Web of Science ®Google Scholar
• Labrie F. Blockade of testicular and adrenal androgens in prostate cancer treatment. Nat Rev Urol 2011;8:73–85
   PubMed Web of Science ®Google Scholar
• Qiu W, Zhou M, Mazumdar M, et al. Structure-based inhibitor design for an enzyme that binds different steroids: a potent inhibitor for human type 5 17β-hydroxysteroid dehydrogenase. J Biol Chem 2007;282:8368–79
   PubMed Web of Science ®Google Scholar
• Zhou M, Qiu W, Chang HJ, et al. Purification, crystallization and preliminary X-ray diffraction results of human 17β-hydroxysteroid dehydrogenase type 5. Acta Crystallogr Sect D: Biol Crystallogr 2002;58:1048–50
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Suzuki T, Nakabayashi M, et al. In situ androgen producing enzymes in human prostate cancer. Endocr-Relat Cancer 2005;12:101–7
   PubMed Web of Science ®Google Scholar
• Marchais-Oberwinkler S, Henn C, Möller G, et al. 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development. J Steroid Biochem Mol Biol 2011;125:66–82
   PubMed Web of Science ®Google Scholar
• Garrido M, Cabeza M, Cortés F, et al. Cytotoxic effect of novel dehydroepiandrosterone derivatives on different cancer cell lines. Eur J Med Chem 2013;68:301–11
   PubMed Web of Science ®Google Scholar
• Iype PT, Iype LE, Verma M, Kaighn ME. Establishment and characterization of immortalized human cell lines from prostatic carcinoma and benign prostatic hyperplasia. Int J Oncol 1998;12:257–63
   PubMed Web of Science ®Google Scholar
• Castagnetta LAM, Carruba G, Traina A, et al. Expression of different 17β-hydroxysteroid dehydrogenase types and their activities in human prostate cancer cells. Endocrinology 1997;138:4876–82
   PubMed Web of Science ®Google Scholar
• Sharifi N, Auchus RJ. Steroid biosynthesis and prostate cancer. Steroids 2012;77:719–26
   PubMed Web of Science ®Google Scholar
• Dewang PM, Kim D-K. Synthesis and biological evaluation of 2-pyridyl-substituted pyrazoles and imidazoles as transforming growth factor-β type 1 receptor kinase inhibitors. Bioorganic Med Chem Lett 2010;20:4228–32
   PubMed Web of Science ®Google Scholar
• Trapani G, Dazzi L, Pisu MG, et al. A rapid method for obtaining finasteride, a 5α-reductase inhibitor, from commercial tablets. Brain Res Protoc 2002;9:130–4
   PubMedGoogle Scholar
• Njar VCO, Kato K, Nnane IP, et al. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17α-hydroxylase-C17,20-lyase (P45017α): potential agents for the yreatment of prostate cancer. J Med Chem 1998;41:902–12
   PubMed Web of Science ®Google Scholar
• Cabeza M, Trejo KV, González C, et al. Steroidal 5α-reductase inhibitors using 4-androstenedione as substrate. J Enzyme Inhib Med Chem 2011;26:712–19
   PubMed Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. Anal Biochem 1976;72:248–54
   PubMed Web of Science ®Google Scholar
• Cabeza M, Heuze Y, Quintana H, Bratoeff E. Comparison between two different hamster models used for the determination of testosterone and finasteride activity. Asian J Anim Vet Adv 2010;5:202–9
   Web of Science ®Google Scholar
• Lineweaver H, Burk D. The determination of enzyme dissociation constants. J Am Chem Soc 1934;56:658–66
   Web of Science ®Google Scholar
• Luu-The V. Assessment of steroidogenesis and steroidogenic enzyme functions. J Steroid Biochem Mol Biol 2013;137:176–82
   PubMed Web of Science ®Google Scholar
• Nahoum V, Gangloff A, Legrand P, et al. Structure of the human 3α-hydroxysteroid dehydrogenase type 3 in complex with testosterone and NADP at 1.25-Å resolution. J Biol Chem 2001;276:42091–8
   PubMed Web of Science ®Google Scholar
• Koh E, Noda T, Kanaya J, Namiki M. Differential expression of 17β-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues. Prostate 2002;53:154–9
   PubMed Web of Science ®Google Scholar
• Vicker N, Sharland CM, Heaton WB, et al. The design of novel 17β-hydroxysteroid dehydrogenase type 3 inhibitors. Mol Cell Endocrinol 2009;301:259–65
   PubMed Web of Science ®Google Scholar
• Johnson KA, Goody RS. The original Michaelis constant: translation of the 1913 Michaelis–Menten paper. Biochemistry 2011;50:8264–9
   PubMed Web of Science ®Google Scholar
• McGoldrick C, Jiang Y-L, Paromov V, et al. Identification of oxidized protein hydrolase as a potential prodrug target in prostate cancer. BMC Cancer 2014;14:77
   PubMed Web of Science ®Google Scholar
• Aldridge WN. Serum esterases. I. Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate, and a method for their determination. Biochem J 1953;53:110–17
   PubMed Web of Science ®Google Scholar
• DeVore NM, Scott EE. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. Nature 2012;482:116–19
   PubMed Web of Science ®Google Scholar
• O'Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17[alpha]-hydroxylase//C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90:2317–25
   PubMed Web of Science ®Google Scholar
• Auchus RJ, Yu MK, Nguyen S, Mundle SD. Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. Oncologist 2014;19:1231–40
   PubMed Web of Science ®Google Scholar
• Délos S, Carsol J-L, Fina F, et al. 5α-Reductase and 17β-hydroxysteroid dehydrogenase expression in epithelial cells from hyperplastic and malignant human prostate. Int J Cancer 1998;75:840–6
   PubMed Web of Science ®Google Scholar